PE20210122A1 - Composiciones de edb que se dirigen a il-12 - Google Patents

Composiciones de edb que se dirigen a il-12

Info

Publication number
PE20210122A1
PE20210122A1 PE2020001190A PE2020001190A PE20210122A1 PE 20210122 A1 PE20210122 A1 PE 20210122A1 PE 2020001190 A PE2020001190 A PE 2020001190A PE 2020001190 A PE2020001190 A PE 2020001190A PE 20210122 A1 PE20210122 A1 PE 20210122A1
Authority
PE
Peru
Prior art keywords
protein
edb
binding domain
composition
subunit
Prior art date
Application number
PE2020001190A
Other languages
English (en)
Spanish (es)
Inventor
Alessandra Villa
Mattia Matasci
Tiziano Ongaro
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of PE20210122A1 publication Critical patent/PE20210122A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2020001190A 2018-02-09 2019-02-08 Composiciones de edb que se dirigen a il-12 PE20210122A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18156141 2018-02-09
EP18179313 2018-06-22
PCT/EP2019/053136 WO2019154986A1 (en) 2018-02-09 2019-02-08 Edb targeting il-12 compositions

Publications (1)

Publication Number Publication Date
PE20210122A1 true PE20210122A1 (es) 2021-01-19

Family

ID=65268973

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001190A PE20210122A1 (es) 2018-02-09 2019-02-08 Composiciones de edb que se dirigen a il-12

Country Status (25)

Country Link
US (1) US12173044B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749372B1 (cg-RX-API-DMAC7.html)
JP (2) JP7279054B2 (cg-RX-API-DMAC7.html)
KR (2) KR102488801B1 (cg-RX-API-DMAC7.html)
CN (1) CN111683687B (cg-RX-API-DMAC7.html)
AU (2) AU2019219201B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020012888A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087488C (cg-RX-API-DMAC7.html)
CL (1) CL2020002052A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009737A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200342A (cg-RX-API-DMAC7.html)
CU (1) CU20200054A7 (cg-RX-API-DMAC7.html)
EC (1) ECSP20047171A (cg-RX-API-DMAC7.html)
ES (1) ES3035714T3 (cg-RX-API-DMAC7.html)
IL (1) IL275713A (cg-RX-API-DMAC7.html)
JO (1) JOP20200193A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008231A (cg-RX-API-DMAC7.html)
MY (1) MY200700A (cg-RX-API-DMAC7.html)
PE (1) PE20210122A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551230A1 (cg-RX-API-DMAC7.html)
RU (2) RU2758143C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006334XA (cg-RX-API-DMAC7.html)
TW (1) TWI844524B (cg-RX-API-DMAC7.html)
UY (1) UY38074A (cg-RX-API-DMAC7.html)
WO (1) WO2019154986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
SG11202100935TA (en) * 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
KR102524247B1 (ko) 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
US20230312726A1 (en) * 2020-04-14 2023-10-05 Philogen S.P.A. Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법
US20250073239A1 (en) * 2022-01-04 2025-03-06 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
EP4780495A1 (en) 2023-09-19 2026-07-29 Philochem AG Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025251110A1 (en) * 2024-06-03 2025-12-11 Selvax Pty Ltd Anti-cd40 antibody il-2 fusion proteins
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
WO2026013184A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Fusion protein peptide linkers and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
ES2337566T3 (es) 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
MX2007013875A (es) 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
ES2872964T3 (es) * 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
JP2016519111A (ja) * 2013-04-26 2016-06-30 フィロゲン エスピーエー 細胞外マトリックス成分に対する抗体にコンジュゲートしたil4
AU2016334401A1 (en) * 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
AU2018226215B2 (en) 2017-02-24 2019-11-21 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
EP3634999A1 (en) * 2017-06-07 2020-04-15 Philogen S.p.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物

Also Published As

Publication number Publication date
JP7279054B2 (ja) 2023-05-22
NZ766787A (en) 2024-05-31
WO2019154986A1 (en) 2019-08-15
KR102488801B1 (ko) 2023-01-13
ECSP20047171A (es) 2020-09-30
CO2020009737A2 (es) 2020-08-21
JP2021513536A (ja) 2021-05-27
AU2019219201B2 (en) 2021-07-08
TW201934136A (zh) 2019-09-01
US20200397915A1 (en) 2020-12-24
CA3087488C (en) 2021-11-02
RU2021130306A (ru) 2021-11-10
MX2020008231A (es) 2020-09-25
AU2021203986A1 (en) 2021-07-08
PH12020551230A1 (en) 2021-05-17
UY38074A (es) 2019-10-01
EP3749372C0 (en) 2025-04-16
KR102259085B1 (ko) 2021-06-03
EP3749372A1 (en) 2020-12-16
RU2758143C1 (ru) 2021-10-26
AU2019219201A1 (en) 2020-07-23
KR20210063467A (ko) 2021-06-01
CN111683687A (zh) 2020-09-18
JP2023113648A (ja) 2023-08-16
CR20200342A (es) 2020-10-19
JOP20200193A1 (ar) 2020-08-06
CL2020002052A1 (es) 2021-01-04
TWI844524B (zh) 2024-06-11
US12173044B2 (en) 2024-12-24
CA3087488A1 (en) 2019-08-15
MY200700A (en) 2024-01-11
IL275713A (en) 2020-08-31
KR20200109380A (ko) 2020-09-22
ES3035714T3 (en) 2025-09-08
SG11202006334XA (en) 2020-08-28
BR112020012888A2 (pt) 2020-12-08
EP3749372B1 (en) 2025-04-16
CN111683687B (zh) 2024-08-02
CU20200054A7 (es) 2021-05-12

Similar Documents

Publication Publication Date Title
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
CY1123192T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldν6)
BR112021024236A2 (pt) Proteínas multiespecíficas
CY1116964T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MX2022008740A (es) Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
MX2021007925A (es) Inhibidores irreversibles de la interaccion menina-mll.
EA202190189A1 (ru) Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
SA519410253B1 (ar) Erk1/2 مشتق 6- بيريميدين أيزوإندول كمثبط
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
CL2019001136A1 (es) Inmunoglobulinas y usos de estas.
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
PE20211225A1 (es) Constructos de arni para inhibir la expresion de pnpla3
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
MX393740B (es) Anticuerpos contra alfa-sinucleina y sus usos.
MX2021006945A (es) Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas.
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
PH12021553306A1 (en) Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof
WO2018191363A8 (en) Targeted combination therapy
BR112022000297A2 (pt) Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.